What should be considered when using the PCE to estimate 10-year ASCVD risk in patients?
When using the PCE to estimate 10-year ASCVD risk in patients, clinicians should consider the PCE's best validation among non-Hispanic whites and non-Hispanic blacks living in the United States. Additionally, when the PCE may overestimate or underestimate risk in other or some non-U.S. populations, clinicians may consider the use of another risk prediction tool as an alternative to the PCE if the tool was validated in a population with characteristics similar to those of the evaluated patient.